Skip to main content
SpringerLink
Log in

Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cranney A et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570–578

    Article  CAS  Google Scholar 

  2. Michalskà D et al. (2006) The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 91: 870–877

    Article  Google Scholar 

  3. Ettinger B et al. (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19: 745–751

    Article  CAS  Google Scholar 

  4. Seeman E et al. (2007) Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int 18: 711–719

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Internal Medicine, Viale Pieraccini 6, 50139 Florence, Italy m.brandi@dmi.unifi.it

Authors and Affiliations

  1. ML Brandi is Full Professor of Endocrinology in the Department of Internal Medicine at the University of Florence, Florence, Italy.,

    Maria Luisa Brandi

Authors
  1. Maria Luisa Brandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandi, M. Is yearly intravenous zoledronic acid comparable to weekly oral alendronate for postmenopausal osteoporosis?. Nat Rev Endocrinol 4, 20–21 (2008). https://doi.org/10.1038/ncpendmet0673

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0673

  • Springer Nature Limited

Search

Navigation